Search the GHTC website

Global health R&D delivers for Oregon

US government investment in global health R&D has delivered

$293 million
to Oregon research institutions
4,000+ new jobs
for Oregon
Oregon's top USG-funded global health R&D institutions

Oregon's top USG-funded global health R&D institutions

Oregon Health and Science University
$234.3 million
Oregon State University
$16.1 million
Portland State University
$13.9 million
DesignMedix Inc.
$6.4 million
Portland VA Research Foundation
$4.3 million
Viti Inc.*
$4.3 million
Hemex Health
$3.9 million
Sedia Biosciences Corporation
$3.9 million
Najít Technologies Inc.
$3 million
University of Oregon
$1.1 million
Mabdx Inc.
$982 thousand
Pacific University
$407 thousand
Virogenomics Inc.
$269 thousand
Thermocap Laboratories
$259 thousand
Undisclosed OR-based industry recipients
$96 thousand

Oregon's top areas of global health R&D by USG funding

Neglected tropical diseases
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Reproductive health
Arenaviral hemorrhagic fevers (including Lassa fever)
Bacterial pneumonia & meningitis
Diarrheal diseases
Emergent non-polio enteroviruses (including EV71, D68)
Filoviral diseases (including Ebola, Marburg)
Hepatitis B
Multi-disease/health area R&D
Salmonella infections
Global health R&D at work in Oregon

Researchers at Oregon Health & Science University are developing what could become the first-ever treatment for chikungunya, a mosquito-borne disease that causes debilitating joint and muscle pain. The research team has discovered an antiviral compound that has shown promise in reducing the virus and joint symptoms in animal studies, which they next plan to advance into human clinical trials. There is currently no approved specific treatment for this virus that has infected an estimated 3 million people in the Americas since it arrived in the Caribbean several years ago.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: PATH/Patrick McKern